Browne L Daniel 4
4 · Revance Therapeutics, Inc. · Filed Mar 19, 2019
Insider Transaction Report
Form 4
Browne L Daniel
DirectorCEO and President
Transactions
- Sale
Common Stock
2019-03-18$15.51/sh−11,613$180,068→ 151,193 total - Tax Payment
Common Stock
2019-03-15$15.45/sh−3,256$50,305→ 165,687 total - Tax Payment
Common Stock
2019-03-15$15.45/sh−2,881$44,511→ 162,806 total
Holdings
- 409(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Represents the number of shares withheld by and surrendered to the issuer on March 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 28,250 shares. The RSA vests in three equal annual installments from March 15, 2018, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- [F2]Represents the number of shares withheld by and surrendered to the issuer on March 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of an RSA for 25,000 shares. The RSA vests in three equal annual installments from March 15, 2016, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- [F3]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
- [F4]The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.19 to $15.74. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F5]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.